




FIG. 1




FIG. 2A

Patient Characteristics	N=56 (%)
Age (median, range)	64 (35-86)
Gender	
Female	26 (46)
Male	30 (54)
LDH	
>ULN	27 (48)
Normal	27 (48)
N/A	2 (4)
Performance Status	
0	45 (80)
1	11 (20)
# prior lines therapy	
0	16 (29)
1	17 (30)
2	12 (21)
=3	8 (14)
N/A	3 (5)
Prior tebentafusp	9 (16)

FIG. 2B

	Placebo	Group 1	Group 2	Group 3	Group 4	Group 5	Group 6	Group 7	Group 8	Group 9	Group 10	Group 11	Group 12	Group 13
	Cohort A Summary n (%)	Cohort A SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)	Cohort A 4mg SD-101 n (%)
All listed events are related to SD-101 (n and n/total)														
Treatment-related AEs (TRAE) (any grade)	5 (32)	0	0	0	0	0	0	0	0	0	0	0	0	0
DLTs	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SAEs	1 (6)	0	0	0	0	0	0	0	0	0	0	0	0	0
≥G3 events (%)	1 (6)	0	0	0	0	0	0	0	0	0	0	0	0	0
Serious G3/G4 TRAEs	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Most common AEs														
-Gastrointestinal Disorders	3 (23)	0	0	0	0	0	0	0	0	0	0	0	0	0
-Fatigue	2 (15)	0	0	0	0	0	0	0	0	0	0	0	0	0
-Skin Disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-Fever	2 (15)	0	0	0	0	0	0	0	0	0	0	0	0	0
-Administration Site Conditions	1 (8)	0	0	0	0	0	0	0	0	0	0	0	0	0
-Increased ALT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-Increased AST	0	0	0	0	0	0	0	0	0	0	0	0	0	0

FIG. 2C




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 12C

Change in Protein Expression on Circulating
NK Cells (Day 1 - Day 36)




FIG. 12D

Change in Protein Expression Patterns on Circulating
NK Cells (Day 1 - Day 36)




FIG. 12E




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F




FIG. 14G




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B

Change in Tumor Pathway Scores from Baseline to Day 57
Split by cohort




FIG. 17C

Change in Tumor Pathway Scores from Baseline to Day 57

Split by dose




FIG. 17D

Change in PBMC Pathway Scores from Baseline to Day 36

Split by cohort




FIG. 17E

Change in PBMC Pathway Scores from Baseline to Day 36

Split by dose




FIG. 17F

Change in Tumor Gene Expression Levels from Baseline to Day 57

Split by cohort




FIG. 17G

Change in Tumor Gene Expression Levels from Baseline to Day 57

Split by dose




FIG. 17H

Change in Tumor Gene Expression Levels from Baseline to Day 57

Split by cohort




FIG. 17I

Change in Tumor Gene Expression Levels from Baseline to Day 57

Split by dose




FIG. 17J

Change in PBMC Gene Expression Levels from Baseline to Day 36
Split by cohort




FIG. 17K

Change in PBMC Gene Expression Levels from Baseline to Day 36
Split by dose




FIG. 17L

Change in PBMC Gene Expression Levels from Baseline to Day 36




FIG. 17M

Change in PBMC Gene Expression Levels from Baseline to Day 36




FIG. 17N




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 19D




FIG. 19E





FIG. 19F






FIG. 21A




FIG. 21B




FIG. 21C




FIG. 21D




FIG. 21E




FIG. 21F

- Cohort A (n=13)
- ▲ Cohort B (n=19)
- ★ Cohort C (n=10)




FIG. 22A




FIG. 22B




FIG. 22C




FIG. 22D




FIG. 22E




FIG. 22F

- Cohort B 2mg (n=5)
- ▲ Cohort B 4mg (n=6)
- ★ Cohort B 8mg (n=8)

Change in Protein Expression on Circulating CD8⁺ T Cells (Day 1 - Day 36)




FIG. 23B

Change in Protein Expression Patterns on Circulating NK Cells (Day 1 - Day 36)




FIG. 23D

Change in Protein Expression on Circulating CD8⁺ T cells (Day 1 - Day 36)




FIG. 23A

Change in Protein Expression on Circulating NK Cells (Day 1 - Day 36)




FIG. 23C

Best On-Treatment RECIST Response for Patients
Treated with SD-101 + Nivo or SD-101 + Ipi + Nivo




FIG. 24A

Best On-Treatment RECIST Response for Patients
Treated with Nelitolimod + Nivo or
Nelitolimod+ Ipi + Nivo




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 25C




FIG. 25D




FIG. 25E

Change in Cell Densities Within Tumors from Baseline to Day 57
Split by cohort




FIG. 26A

Change in Cell Densities Within Tumors from Baseline to Day 57




FIG. 26B

Change in Cell Densities Within Tumors from Baseline to Day 57




FIG. 26C

Change in Cell Densities Within Tumors from Baseline to Day 57




FIG. 26D

Change in Cell Densities Within Tumors from Baseline to Day 57




FIG. 26E

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by dose




FIG. 26F

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by cohort




FIG. 26G

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by dose




FIG. 26H

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by cohort




FIG. 26I

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by dose




FIG. 26J

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by cohort




FIG. 26K

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by dose




FIG. 26L

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by cohort




FIG. 26M

Change in Cell Densities Within Tumors from Baseline to Day 57

Split by dose




FIG. 26N

Change in Plasma Immune Markers from Baseline to Day 36

Split by cohort




FIG. 27A

Change in Plasma Immune Markers from Baseline to Day 36

Split by dose




FIG. 27B

Change in Plasma Immune Markers from Baseline to Day 36

Split by cohort




FIG. 27C

Change in Plasma Immune Markers from Baseline to Day 36

Split by dose




FIG. 27D

Change in Plasma Immune Markers from Baseline to Day 36

Split by cohort




FIG. 27E

Change in Plasma Immune Markers from Baseline to Day 36
Split by dose




FIG. 27F

Change in Plasma Immune Markers from Baseline to Day 36
Split by cohort




FIG. 27G




FIG. 27H